“Bimekizumab Efficacy and Safety Through 2 years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II trials and Open-Label Extension BE HEARD EXT” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s473. doi:10.25251/skin.8.supp.473.